Immunotherapy of cancer using genetically engineered GD2-specific T cells
AssigneeBaylor College of Medicine
InventorsMalcolm Brenner, Gianpietro Dotti, Nabil Ahmed, Claudia Rossig, Stephen M. G. Gottschalk, Zakaria Grada
Life of this patent
Estimating the term…
Abstract
The present invention concerns immunotherapy for cancers having cells that comprise the ganglioside GD2 antigen. In specific embodiment, T cells having a chimeric receptor that targets GD2 is employed. In particular cases, the chimeric receptor comprises antibody, cytoplasmic signaling domain from the T cell receptor, and/or costimulatory molecule(s).
Claims5
A method of treating melanoma or non small cell lung cancer in an individual, comprising the steps of administering to an individual cytotoxic T lymphocytes having a chimeric receptor that recognizes a GD2 antigen on the surface of cancer cells, wherein the chimeric receptor comprises the cytoplasmic signaling domain of the T-cell receptor zeta chain and comprises the cytoplasmic signaling domain of one or more costimulatory molecules selected from the group consisting of CD28, OX40, 4-1BB, and a combination thereof.
Dependencies are inferred from the claim text.